Head-to-head · WeighScore
Breeze Meds vs myRocky
The verdict
Breeze Meds takes it — 72.4/100 to 51.4/100.
Breeze Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Charges nothing until a provider approves you — but keeps its pricing inside the intake.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Breeze Meds | myRocky |
|---|---|---|
| WeighScore | 72.4/100 | 51.4/100 |
| Grade | C | C |
| Scorecard rank | #55 | #487 |
| Semaglutide | From $199/mo | Not disclosed |
| Tirzepatide | From $299/mo first month, $399/mo thereafter | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #55 · C
Strengths
- Nothing charged until a provider approves you, and the consult is free if you go ahead
- One inclusive price covering consult, medication, supplies, shipping and support
- LegitScript certified, all 50 states, cancel or change plan at any time
- NAD+ injections offered alongside the GLP-1 line
Where it loses points
- The public site names no molecule behind its "from $199" — tirzepatide pricing appears only inside the intake
- Every quoted figure is for the LOWEST dose; the funnel says higher doses may cost more
- An $80 consultation fee applies if you are approved and then decline
- Injection only, compounded only, with no published lab programme
Graded #487 · C
Strengths
- Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
- LegitScript Approved
- 42-state coverage with an 8-state expansion roadmap published
- Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription
Where it loses points
- Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
- Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
- Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
- Brand-only — no compounded option for cost-sensitive patients
- $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.